Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Sangamo Therapeutics

Clinical trials sponsored by Sangamo Therapeutics, explained in plain language.

Sangamo Therapeutics SGMO NASDAQ

Biotechnology company developing gene therapies and genome editing.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Trials to join now! 1 Not yet finished but already full! 2 Completed 3 Terminated 1

Gene therapy targets chronic nerve pain in new trial

Disease control Recruiting now

This study tests a one-time gene therapy called ST-503 for people with chronic pain from small fiber neuropathy that hasn't improved with standard treatments. The therapy aims to block pain signals before they reach the brain. The trial involves 27 adults and compares the gene th…

Phase: PHASE1, PHASE2 • Sponsor: Sangamo Therapeutics • Aim: Disease control

Last updated Jun 27, 2026 13:00 UTC